Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CytomX Therapeutics Q3 EPS $0.04 Beats $(0.19) Estimate, Sales $26.38M Beat $14.14M Estimate

Author: Benzinga Newsdesk | November 07, 2023 06:35pm
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.19) by 121.05 percent. This is a 111.43 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $26.38 million which beat the analyst consensus estimate of $14.14 million by 86.59 percent. This is a 55.98 percent increase over sales of $16.91 million the same period last year.

Posted In: CTMX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist